Villepinte (France) - October 10, 2019 (8:30 CEST) - Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, today announced that it has signed an exclusive agreement with icometrix for the distribution in France, Italy and Brazil of icobrain, their Saas (Software as a Service) artificial intelligence-based medical imaging solution.

Icobrain is designed to help radiologists and neurologists diagnose and monitor patients with neurological disorders. The Artificial Intelligence software extracts clinically meaningful information from brain CT or MRIs scans of patients with multiple sclerosis, dementia or brain injury. Icobrain can therefore be used to automate the currently manual process of identifying, marking and quantifying volumes of brain structures identified.

Icobrain has obtained marketing authorizations in numerous countries, including the United States, Europe, Canada, Brazil, Australia, Japan and India and is already used in more than 100 hospitals and imaging centers across the world, as well as in clinical studies from major global pharmaceutical companies.

"This agreement will allow more patients with neurological disorders to benefit from the icobrain AI technology. It will also allow Guerbet to expand its portfolio of augmented intelligence solutions beyond oncology, with the same aim of helping radiologists diagnose better and faster than ever before," said François Nicolas, Chief Digital Officer for Guerbet.

"There is a strong medical need to help radiologists, neurologists and patients with neurological disorders. This collaboration with Guerbet will allow us to serve hospitals in France, Italy and Brazil with the best support", says Wim Van Hecke, CEO of icometrix. "Guerbet has many years of expertise in the radiology market and has a great reputation. We're very much looking forward to this strategic partnership".


About Guerbet
Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com.


About icometrix
icometrix (Leuven, Belgium; Chicago, USA) is the world leader in software solutions to obtain clinically meaningful data from brain MRI and CT scans for patients with Multiple Sclerosis, Traumatic Brain Injury, Epilepsy, Alzheimer's Disease, Stroke, etc. The fully automated icobrain software is FDA approved and has market approval in Europe, Japan, Canada, Brazil, and Australia. Today, icometrix is internationally active, the icobrain software is used in 100+ hospitals and icometrix works with the largest pharmaceutical and health tech companies.

Alzheimers/Neurology Homepage